476 results on '"Massuti, Bartomeu"'
Search Results
152. The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
153. Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: Results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years.
154. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
155. The predictive role of integrated BRCA1 and HERC2 mRNA expression in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based first-line chemotherapy.
156. Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).
157. Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients.
158. Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC): TTD 08-02.
159. Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
160. Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib.
161. Long-term survivors with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) chemotherapy (CT) plus bevacizumab (B) and maintenance (mtc) B.
162. EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.
163. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)—Final results.
164. Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.
165. DNA repair components modulating the function of breast cancer susceptibility gene 1 (BRCA1) in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based chemotherapy.
166. Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.
167. MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations.
168. High mRNA expression of LMO4, a BRCA1 downregulator, correlates with better prognosis in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
169. Abstract 1727: Correlation between BRCA1 and LMO4 mRNA expression levels in Erlotinib-treated non small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
170. Abstract 4596: Missense mutations in the p53 DNA-binding motifs (DBMs) are associated with shorter time to progression (TTP) in erlotinib-treated, EGFR-mutated patients
171. First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study
172. Abstract 4110: NanoString multiple target profiling identifies AEG-1 as an essential predictor of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC)
173. Abstract 4112: De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy
174. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
175. Predicting Response to Chemotherapy With Early-Stage Lung Cancer
176. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
177. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
178. Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer
179. Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung
180. Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901
181. P2-104: Role of ERCC1, XRCC3, Aurora A and TGFBR1 single nucleotide polymorphisms (SNP) and CHFR and 14-3-3 sigma methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer (NSCLC) patients (p)
182. D4-06: Potential role of molecular markers expression to improve mediastinal nodes staging from resected stage I non-small cell lung cancer (NSCLC)
183. B2-01: The NATCH trial: chemotherapy toxicity and response on the neoadjuvant arm
184. P2-242: First-line treatment with vinorelbine (VRL) plus cisplatin (CDDP) for patients with advanced non-small-cell lung cancer (NSCLC): Molecular correlates
185. P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations
186. Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer
187. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
188. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
189. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
190. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
191. O-47 XPD polymorphisms identify a subset of non-small-cell lung cancer (NSCLC) patients (p) with poor survival with gemcitabine (gem)/cisplatin (cis)
192. P-215 Analysis of xeroderma pigmentosum complementation group D (XPD) in the NATCH trial: a neoadjuvant/adjuvant paclitaxel/carboplatin trial in early non-small-cell lung cancer (NSCLC)
193. P-476 Pleural and serum DNA in patients with cancer and pleural effusion: a semi-quantitative diagnostic tool
194. O-2 TWO second-line docetaxel dose-schedules in advanced non-small-cell lung cancer (NSCLC): A Spanish lung cancer group (SLCG) phase III trial
195. P-217 K-ras mutations in serum DNA of early non-small-cell lung cancer (NSCLC) patients (p): A genetic analysis of an ongoing randomized neoadjuvant/adjuvant paclitaxel/carboplatin trial
196. P-203 SLCG 9901: phase II trial with cisplatin (cis), gemcitabine (gem) and docetaxel (doc) as neoadjuvant treatment in stage IIIA N2 and T4N0-1 non-small cell lung cancer (NSCLC) patients
197. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
198. Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
199. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
200. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.